Results 221 to 230 of about 249,739 (290)

Subtype‐specific enhancer RNAs define transcriptional regulators and prognosis in breast cancers

Molecular Oncology, EarlyView.
This study employed machine learning methodologies to perform the subtype‐specific classification of RNA‐seq data sets, which are mapped on enhancers from TCGA‐derived breast cancer patients. Their integration with gene expression (referred to as ProxCReAM eRNAs) and chromatin accessibility profiles has the potential to identify lineage‐specific and ...
Aamena Y. Patel, Peyman Zarrineh, Nathnael T. Tuffa, Jigar H. Sheth, Sumitra Mohan, Mudassar Iqbal, Sankari Nagarajan   +6 more
wiley   +1 more source

High daily dose Short COurse PrimaquinE after G6PD testing for the radical cure of Plasmodium vivax malaria in Indonesia and Papua New Guinea: the SCOPE implementation study protocol. [PDF]

BMC Infect Dis
SCOPE Study Group.
europepmc   +1 more source

Genetic attenuation of ALDH1A1 increases metastatic potential and aggressiveness in colorectal cancer

Molecular Oncology, EarlyView.
Aldehyde dehydrogenase 1A1 (ALDH1A1) is a cancer stem cell marker in several malignancies. We established a novel epithelial cell line from rectal adenocarcinoma with unique overexpression of this enzyme. Genetic attenuation of ALDH1A1 led to increased invasive capacity and metastatic potential, the inhibition of proliferation activity, and ultimately ...
Martina Poturnajova, Zuzana Kozovska, Ondrej Pos, Kristina Pavlov, Sachin Gulati, Peter Makovicky, Kristina Jakic, Monika Burikova, Eva Sedlackova, Barbora Svitkova, Silvia Tyciakova, Vojtech Bystry, Nicolas Blavet, Boris Tichy, Matej Hrnciar, Jaroslav Budis, Miroslav Tomas, Peter Dubovan, Georgina Kolnikova, Veronika Repaska, Nikoleta Mojzesova, Eva Zomborska, Daniel Pindak, Michal Mego, Tomas Szemes, Miroslava Matuskova   +25 more
wiley   +1 more source

Safety, tolerability, and efficacy of high versus low-dose, short versus long-course daily primaquine for the radical cure of uncomplicated Plasmodium vivax malaria in children under 15 years of age: an open-label, non-inferiority, randomized controlled trial (CHILDPRIM). [PDF]

Malar J
Pacheco ALO, Omena AG, Baía-da-Silva DC, Jardim TAP, Silva DCB, Lopes APB, Barbosa LRA, Souza IG, Araujo RF, Nogueira LOS, Vale SCN, Melo GC, Cordeiro JSM, Bassat Q, Sampaio VS, Lima VDS, Martinez-Espinosa FE, Mourão MPG, Monteiro WM, Alecrim MGC, Brito-Sousa JD, Lacerda MVG.   +21 more
europepmc   +1 more source

Active Pharmacovigilance for Primaquine Radical Cure of Plasmodium vivax Malaria in Odisha, India. [PDF]

Am J Trop Med Hyg, 2022
Anvikar AR, Sahu P, Pradhan MM, Sharma S, Ahmed N, Yadav CP, Pradhan S, Duparc S, Grewal Daumerie P, Valecha N.   +9 more
europepmc   +1 more source

Dimethyl fumarate combined with cisplatin at subcytotoxic doses sensitizes cervical cancer toward ferroptosis and apoptosis through GSH restriction and p53 (re)activation

Molecular Oncology, EarlyView.
Dimethyl fumarate (DMF) reduces growth of HPV‐positive cervical cancer spheroids and induces ferroptosis in cervical cancer cells via blocking SLC7A11/Glutathione (GSH) axis. Combination of subcytotoxic doses of DMF and cisplatin (CDDP) further suppresses spheroid growth and drives cell death in 2D culture models.
Carolina Punziano, Giuseppina Minopoli, Simona Romano, Laura Marrone, Katia Aquilano, Maria Lina Tornesello, Raffaella Faraonio   +6 more
wiley   +1 more source

Co-design of a routine clinical review to improve the safety of high dose radical cure treatment for Plasmodium vivax malaria: findings from Cambodia and Ethiopia. [PDF]

Malar J
Cassidy-Seyoum SA, Mwaura M, Chheng K, Kejela M, Korra KG, Wodaj T, Degaga TS, Hsiang MS, von Seidlein L, Tripura R, Adhikari B, Ley B, Lek D, Price RN, Engel N, Thriemer K.   +15 more
europepmc   +1 more source

Safety and Efficacy of Tafenoquine for Plasmodium vivax Malaria Prophylaxis and Radical Cure: Overview and Perspectives. [PDF]

Ther Clin Risk Manag, 2021
Markus MB.
europepmc   +1 more source

Targeted modulation of IGFL2‐AS1 reveals its translational potential in cervical adenocarcinoma

Molecular Oncology, EarlyView.
Cervical adenocarcinoma patients face worse outcomes than squamous cell carcinoma counterparts despite similar treatment. The identification of IGFL2‐AS1's differential expression provides a molecular basis for distinguishing these histotypes, paving the way for personalized therapies and improved survival in vulnerable populations globally.
Ricardo Cesar Cintra, Lucca Paolo Hsu Helmich, Daniel Rodrigues de Bastos, Laura Sichero, Patrícia Savio de Araujo‐Souza, Fabio Passetti, Luisa Lina Villa   +6 more
wiley   +1 more source

Prospective observational study to assess the feasibility and safety of appropriate <i>Plasmodium vivax</i> radical cure with tafenoquine or primaquine after quantitative G6PD testing during pilot implementation in Thailand. [PDF]

BMJ Glob Health
Sudathip P, Khantikul N, Saejeng A, Duparc S, Grewal Daumerie P, Lynch C, Jambert E, Viboonsanti S, Areechokchai D, Kanjanasuwan J, Thong-Ard T, Kowsurat P, Borghini-Fuhrer I, Padungtod C.   +13 more
europepmc   +1 more source